Austin Financial Services (AFS) closed a $2.5 million ABL facility to a life sciences company that operates in the field of cell and gene therapy used for research and development, clinical trials and commercial production by academic, biotech, diagnostic, pharmaceutical and contract research organizations. Proceeds from the AFS revolver will provide working capital and support for long-term growth plans.
“We are delighted that an institution of this caliber recognizes our mission and supports our growth through working capital,” the company’s founder and CEO said. “We want to propel the healthcare field into a successful and meaningful future, expanding treatment options, reducing costs and broadening access for those who need it most.”
“AFS is proud to support businesses on the cutting edge of technology,” Jason Anish, president and CEO of AFS, said. “We are committed to providing clients with financing solutions that meet their long-term strategy and mission.”
